Comparative Pharmacology
Head-to-head clinical analysis: ANDROID F versus DANAZOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANDROID F versus DANAZOL.
ANDROID-F vs DANAZOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fingolimod is a sphingosine 1-phosphate receptor modulator that sequesters lymphocytes in lymph nodes, reducing central nervous system immune cell infiltration.
Danazol is a synthetic androgen derived from ethisterone that suppresses pituitary-ovarian axis by inhibiting gonadotropin release, leading to decreased estrogen and progesterone levels. It also has weak androgenic and progestational activity.
Adults: 1 tablet (methyltestosterone 2.5 mg, ethinyl estradiol 0.025 mg) orally once daily, with food.
300-600 mg orally twice daily; maximum 800 mg/day
None Documented
None Documented
2.5-3.5 hours (terminal half-life); oral administration may require multiple daily doses for stable levels.
Clinical Note
moderateDanazol + Tolbutamide
"The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Danazol."
Clinical Note
moderateDanazol + Rosiglitazone
"The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Danazol."
Clinical Note
moderateDanazol + Pioglitazone
"The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Danazol."
Clinical Note
moderateDanazol + Saxagliptin
Terminal elimination half-life is 4-4.5 hours; clinical context: requires multiple daily dosing to maintain therapeutic levels.
Primarily renal (90% as glucuronide and sulfate conjugates, 10% unchanged); small amount biliary/fecal.
Primarily hepatic metabolism; approximately 60% excreted in feces, 30% in urine as metabolites.
Category C
Category C
Androgen/Estrogen Combination
Androgen/Antigonadotropin
"The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Danazol."